摘要
Backgroud Up to date, there is few satisfactory pharmacotherapy, except for aspirin and heparin, to stop the preeclampsia progression. Although the mechanism of preeclampsia is poorly understood, it has been proven to be associated with coagulation activation. Researches on prophylactic and therapeutic application of anticoagulants may benefit the clinical aspects of preeclampsia individuals. This study aimed to evaluate the effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine （PS/PC） microvesicle induced-mouse model. Methods Sixty-six preeclampsia-like pregnant mice, induced by PS/PC microvesicle administration, were randomly divided into six groups. From days 5.5 to 16.5 of pregnancy, each group was respectively treated as follows： a） mice in group C （n=12, control group） were injected with 100 μl of filtered phosphate-buffered saline into the tail vein every day; b） group PE （n=15, preeclampsia model group） were injected in the same way with 100 μl of filtered PS/PC vesicle suspension; c） group H （n=9, group treated with heparin） were injected with 1 unit heparin together with PS/PC vesicle suspension; d） group A （n=10, group treated with aspirin） were injected with 20 μg/g aspirin-DL lysine as well; e） group LD （n=10, group treated with low-dose Danshensu） were injected with 10 μg/g Danshensu; and f） group HD （n=10, group treated with high-dose Danshensu） were injected with 30 μg/g Danshensu. Systolic blood pressure, total urinary protein levels, blood tests for some hemostatic function parameters （mean platelet counts, plasma antithrombin III activity （AT-Ⅲ）, D-D dimmer levels, and thrombin time）, fibrin deposition by phosphotungstic acid hematoxylin staining, and thrombomodulin expression by immunohistochemistry staining in placentas were examined as indices for maternal syndrome. Results Heparin showed significant effects on maternal syndrome of preeclampsia such as hypertension and proteinuria, and different doses of D
Backgroud Up to date, there is few satisfactory pharmacotherapy, except for aspirin and heparin, to stop the preeclampsia progression. Although the mechanism of preeclampsia is poorly understood, it has been proven to be associated with coagulation activation. Researches on prophylactic and therapeutic application of anticoagulants may benefit the clinical aspects of preeclampsia individuals. This study aimed to evaluate the effects of Danshensu on maternal syndrome in phosphatidylserine/phosphatidylcholine （PS/PC） microvesicle induced-mouse model. Methods Sixty-six preeclampsia-like pregnant mice, induced by PS/PC microvesicle administration, were randomly divided into six groups. From days 5.5 to 16.5 of pregnancy, each group was respectively treated as follows： a） mice in group C （n=12, control group） were injected with 100 μl of filtered phosphate-buffered saline into the tail vein every day; b） group PE （n=15, preeclampsia model group） were injected in the same way with 100 μl of filtered PS/PC vesicle suspension; c） group H （n=9, group treated with heparin） were injected with 1 unit heparin together with PS/PC vesicle suspension; d） group A （n=10, group treated with aspirin） were injected with 20 μg/g aspirin-DL lysine as well; e） group LD （n=10, group treated with low-dose Danshensu） were injected with 10 μg/g Danshensu; and f） group HD （n=10, group treated with high-dose Danshensu） were injected with 30 μg/g Danshensu. Systolic blood pressure, total urinary protein levels, blood tests for some hemostatic function parameters （mean platelet counts, plasma antithrombin III activity （AT-Ⅲ）, D-D dimmer levels, and thrombin time）, fibrin deposition by phosphotungstic acid hematoxylin staining, and thrombomodulin expression by immunohistochemistry staining in placentas were examined as indices for maternal syndrome. Results Heparin showed significant effects on maternal syndrome of preeclampsia such as hypertension and proteinuria, and different doses of D
